Printer Friendly

VESTAR FILES SUIT AGAINST LIPOSOME TECHNOLOGY, INC.

 SAN DIMAS, Calif., Jan. 20 /PRNewswire/ -- Vestar, Inc. (NASDAQ: VSTR) today announced that it has filed a suit in Delaware federal court against Liposome Technology, Inc. Vestar's complaint asks the court to declare that a patent obtained yesterday by Liposome Technology is invalid and is not infringed by Vestar's product, AmBisome(R).
 Yesterday, Vestar commented that the methodology described in the Liposome Technology patent appeared not to be relevant to AmBisome. Liposome Technology's patent concerns a process for preventing the alteration in size of liposomes that enclose amphotericin B. It also describes increased toxicity when such size changes occur. Vestar stated that since AmBisome does not change size before freeze drying or after reconstitution back to a liquid solution, Vestar does not need any process to prevent size changes. Vestar further noted that the company believes the size of stability of AmBisome is one of the reasons that the toxicity of AmBisome is so low.
 Vestar, headquartered in San Dimas, Calif., develops, manufactures and markets pharmaceuticals to treat patients with cancer and serious infections, including AIDS. Among the company's proprietary drug delivery technologies are liposomes to encapsulate pharmaceuticals, and lipid prodrug technology for the development of orally active compounds. Since 1989, Vestar has been marketing in Europe AmBisome, a liposomal formulation of amphotericin B, to treat systemic fungal infections. DaunoXome(R), a liposomal formulation of the chemotherapeutic agent daunorubicin, is in development as Vestar's second major product.
 -0- 1/20/93
 /CONTACT: Michael E. Hart, chief financial officer of Vestar, Inc., 714-394-4119 or Marcia A. Kean, executive VP of Feinstein Partners Inc., 617-577-8110/
 (VSTR)


CO: Vestar ST: California IN: MTC SU:

SJ-TM -- NE002 -- 6703 01/20/93 07:59 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 20, 1993
Words:280
Previous Article:NORWEST CORPORATION REPORTS RECORD ANNUAL AND QUARTERLY EARNINGS
Next Article:INDEPENDENCE REPORTS NET INCOME OF $11.5 MILLION FOR 1992; DIVIDEND DECLARED
Topics:


Related Articles
VESTAR FILES COUNTERCLAIM VS. THE LIPOSOME COMPANY: ALLEGES THAT PATENT IS INVALID AND DENIES INFRINGEMENT
THE LIPOSOME COMPANY SUES VESTAR; SUIT CHARGES VESTAR'S AMBISOME INFRINGES LIPOSOME'S PATENT
VESTAR EXPRESSES CONFIDENCE IN PATENT POSITION; WILL VIGOROUSLY CONTEST ALL INFRINGEMENT ALLEGATIONS
THE LIPOSOME COMPANY, INC. REPORTS THIRD QUARTER RESULTS; THIRD QUARTER REVENUES UP 11 PERCENT
VESTAR ISSUES STATEMENT REGARDING PATENT ISSUED TO LIPOSOME TECHNOLOGY, INC.
FUJISAWA USA FILES IND APPLICATION FOR VESTAR'S AMBISOME(R)
COURT FINDS VESTAR DOES NOT INFRINGE LTI PATENT
NEXAGEN AND VESTAR SIGN MERGER AGREEMENT
LIPOSOME TECHNOLOGY, INC. ANNOUNCES JUDGMENT
The Liposome Company and NeXstar Pharmaceuticals Settle Patent Litigation

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters